Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NovoCure Ltd
Report date March 04, 2026 · Filed March 05, 2026
Section 16 reporting ended · disclosed 2026-03-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 422,570 |
Reported balance
After 2026-03-04 transaction · row 1
1 source rowRow 1 · 2026-03-04 · Tax withholding · Disposed 17,638 · Balance 422,570 F1: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2022 Filed Mar 7, 2022 23:26 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 21,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000022 · wf-form4_164669559462387.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,312 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 11, 2022 21:55 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,200 | $11.46 Strike: $11.46 | $13,752.00 |
DisclosureSEC source: 0001645113-22-000032 · wf-form4_164703570445119.xml · derivative · entry 4 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,736 Underlying: Ordinary Shares · 1,200 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 03, 2022 Filed Mar 11, 2022 21:55 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 3,840 | $15.60 Strike: $15.60 | $59,904.00 |
DisclosureSEC source: 0001645113-22-000032 · wf-form4_164703570445119.xml · derivative · entry 3 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,840 shares Expires 2025-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 03, 2022 Filed Mar 11, 2022 21:55 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,200 | $11.46 | $13,752.00 |
DisclosureSEC source: 0001645113-22-000032 · wf-form4_164703570445119.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2022 Filed Mar 11, 2022 21:55 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,840 | $15.60 | $59,904.00 |
DisclosureSEC source: 0001645113-22-000032 · wf-form4_164703570445119.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 22:37 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 46 | $63.82 | $2,935.63 |
DisclosureSEC source: 0001645113-22-000005 · wf-form4_164202703285939.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,804 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 209 | $107.28 | $22,420.68 |
DisclosureSEC source: 0001645113-21-000114 · wf-form4_163597024160717.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,758 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 828 | $138.23 | $114,456.10 |
DisclosureSEC source: 0001645113-21-000108 · wf-form4_163104705924754.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,967 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 2,606 | $0.00 Strike: $69.37 | $0.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 18 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,375 Underlying: Ordinary Shares · 2,606 shares Expires 2030-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,298 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 17 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 Underlying: Ordinary Shares · 7,298 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 2,767 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 16 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,533 Underlying: Ordinary Shares · 2,767 shares Expires 2028-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 8,026 | $0.00 Strike: $21.50 | $0.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 15 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,297 Underlying: Ordinary Shares · 8,026 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,927 | $0.00 Strike: $19.25 | $0.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 14 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,927 shares Expires 2027-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 10,000 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 13 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,840 Underlying: Ordinary Shares · 10,000 shares Expires 2025-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | GiftOrdinary Shares | 1,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 12 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,260 F3 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,606 | $140.90 | $367,185.40 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 11 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,993 Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 2,606 | $69.37 | $180,778.22 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 10 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,298 | $140.90 | $1,028,288.20 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 9 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,993 Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,298 | $47.04 | $343,297.92 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 8 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,767 | $140.90 | $389,870.30 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 7 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,993 Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 2,767 | $32.02 | $88,599.34 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 6 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 8,026 | $140.90 | $1,130,879.45 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 5 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,993 F2 · price: On August 12, 2021, Ms. Cordova sold 8,026 shares in multiple trades at prices ranging from $140.90 to $140.98. The price reported above reflects the weighted average sale price. Ms. Cordova hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 8,026 | $21.50 | $172,559.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 4 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,927 | $141.06 | $836,062.62 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 3 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,993 F1 · price: On August 12, 2021, Ms. Cordova sold 5,927 shares in multiple trades at prices ranging from $140.90 to $141.08. The price reported above reflects the weighted average sale price. Ms. Cordova hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,927 | $19.25 | $114,094.75 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 10,000 | $15.60 | $156,000.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:35 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 100 | $137.12 | $13,712.20 |
DisclosureSEC source: 0001645113-21-000087 · wf-form4_162578013600784.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,993 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 765 | $130.81 | $100,066.59 |
DisclosureSEC source: 0001645113-21-000046 · wf-form4_161541055936007.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,893 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:23 UTC | NovoCure Ltd NVCR · Entity 4494 | GiftOrdinary Shares | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000037 · wf-form4_161523857594813.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,658 F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:23 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 567 | $137.55 | $77,993.12 |
DisclosureSEC source: 0001645113-21-000037 · wf-form4_161523857594813.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,568 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:52 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 20,004 | $0.00 Strike: $153.09 | $0.00 |
DisclosureSEC source: 0001645113-21-000030 · wf-form4_161489829589176.xml · derivative · entry 3 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,004 Underlying: Ordinary Shares · 20,004 shares Expires 2031-03-01 F3 · derivative.exercise_date: Options to buy 20,004 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:52 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 10,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000030 · wf-form4_161489829589176.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,135 F2 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 428 | $152.05 | $65,078.68 |
DisclosureSEC source: 0001645113-21-000030 · wf-form4_161489829589176.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,249 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Share Units vested on February 27, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 1,465 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000022 · wf-form4_161471962569346.xml · derivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,465 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,465 | $149.10 | $218,431.50 |
DisclosureSEC source: 0001645113-21-000022 · wf-form4_161471962569346.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:23 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 230 | $117.41 | $27,004.53 |
DisclosureSEC source: 0001645113-20-000158 · wf-form4_160443857426133.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,212 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 20:38 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 11,336 | $0.00 Strike: $84.68 | $0.00 |
DisclosureSEC source: 0001645113-20-000129 · wf-form4_159925186640377.xml · derivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,336 Underlying: Ordinary Shares · 11,336 shares Expires 2030-08-31 F2 · derivative.exercise_date: Options to buy 11,336 ordinary shares will vest and become exercisable in equal installments on each of September 1, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 20:38 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 5,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000129 · wf-form4_159925186640377.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,442 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on September 1, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.